Active Ingredient History
Icatibant (trade name Firazyr) is a synthetic peptidomimetic drug consisting of ten amino acids, and acts as an effective and specific antagonist of bradykinin B2 receptors. It has been approved in the EU for use in hereditary angioedema, and is under investigation for a number of other conditions in which bradykinin is thought to play a significant role. Icatibant currently has orphan drug status in the United States and FDA approved on August 25, 2011. Icatibant inhibits bradykinin from binding the B2 receptor and thereby treats the clinical symptoms of an acute, episodic attack of HAE. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Angioedema (Phase 4)
Cardiopulmonary Bypass (Phase 2/Phase 3)
COVID-19 (Phase 2/Phase 3)
Fibrinolysis (Phase 2/Phase 3)
General Surgery (Phase 2/Phase 3)
Heart Failure (Phase 4)
Hemodialysis, Home (Phase 2)
Hypotension (Phase 3)
Inflammation (Phase 2/Phase 3)
Joint Diseases (Phase 2)
Mitochondrial Diseases (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue